{"id":"hs-20093","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297389","moleculeType":"Small molecule","molecularWeight":"421.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-20093 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, amplifications, or fusions.","oneSentence":"HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:59.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07464327","phase":"PHASE3","title":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":450},{"nctId":"NCT07462923","phase":"PHASE1","title":"HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2026-01-29","conditions":"Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT07268053","phase":"EARLY_PHASE1","title":"A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2026-02-11","conditions":"Glioblastoma (GBM), Brain Metastasases","enrollment":15},{"nctId":"NCT07230106","phase":"PHASE2","title":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-08","conditions":"Prostate Cancer","enrollment":218},{"nctId":"NCT07186452","phase":"PHASE1","title":"Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-09-23","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT07115446","phase":"PHASE1","title":"Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-08-19","conditions":"Advanced Prostate Cancer","enrollment":63},{"nctId":"NCT07063407","phase":"PHASE1","title":"Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Hansoh Biomedical Co., Ltd","startDate":"2025-07-31","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":50},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":"Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer","enrollment":157},{"nctId":"NCT06963502","phase":"PHASE1","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-30","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer","enrollment":762},{"nctId":"NCT06935409","phase":"PHASE3","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-04-30","conditions":"Osteosarcoma","enrollment":117},{"nctId":"NCT06621563","phase":"PHASE1","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-14","conditions":"Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":780},{"nctId":"NCT06825624","phase":"PHASE1","title":"ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-10-03","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":560},{"nctId":"NCT06112704","phase":"PHASE2","title":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-02-06","conditions":"Advanced Solid Tumor","enrollment":220},{"nctId":"NCT06699576","phase":"PHASE1","title":"ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-20","conditions":"Osteosarcoma, Soft Tissue Sarcoma (STS)","enrollment":448},{"nctId":"NCT06498479","phase":"PHASE3","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-07-04","conditions":"Small Cell Lung Cancer","enrollment":460},{"nctId":"NCT05830123","phase":"PHASE2","title":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2023-06-08","conditions":"Osteosarcoma, Sarcoma","enrollment":170},{"nctId":"NCT06001255","phase":"PHASE2","title":"ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-01-18","conditions":"Metastasis Castration Resistant Prostate Cancer(mCRPC)","enrollment":120},{"nctId":"NCT06007729","phase":"PHASE2","title":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2023-12-18","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":170},{"nctId":"NCT06526624","phase":"PHASE3","title":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-09-30","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":406},{"nctId":"NCT06332170","phase":"PHASE1","title":"ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-04-26","conditions":"Advanced Solid Tumor","enrollment":610},{"nctId":"NCT06052423","phase":"PHASE2","title":"ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-11-30","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":""},{"nctId":"NCT05276609","phase":"PHASE1","title":"ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Hansoh Biomedical Co., Ltd","startDate":"2021-11-28","conditions":"Advanced Solid Tumor","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risvutatug Rezetecan","GSK5764227"],"phase":"phase_3","status":"active","brandName":"HS-20093","genericName":"HS-20093","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}